Jun 20, 2005Signed service agreement with Rigel Pharmaceuticals for Co-Crystal Complex.
Carna Biosciences and CrystalGenomics, Inc. jointly announce the signing of a service agreement with Rigel Pharmaceuticals, Inc. in the field of structure based drug design.
Mar 1, 2005Signed option agreement with Seikagaku Corporation to license the compound.
Carna Biosciences and Seikagaku Corporation have signed an option agreement granting Seikagaku Corporation an exclusive right to enter into a license agreement.
When Seikagaku Corporation exercises the option, Carna Biosciences grants Seikagaku Corporation an exclusive worldwide development and market rights of a drug candidate for psoriasis developed by Carna Biosciences.
It is reported that more than 80 million people in the world are receiving medical treatment for psoriasis.
Feb 21, 2005Named exclusive global distributor for CrystalGenomics, Inc.'s X-ray crystallographic products and services
Carna Biosciences has acquired the sole and exclusive worldwide rights to sell the kinase crystallization related products and services of CrystalGenomics, Inc.